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esponsibility of InstAbstract 2,3-Benzodiazepine (2,3-BDZ) compounds represent a group of structurally diverse, small-
molecule antagonists of (R, S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA)
receptors. Antagonists of AMPA receptors are drug candidates for potential treatment of a number of
neurological disorders such as epilepsy, stroke and amyotrophic lateral sclerosis (ALS). How to make
better inhibitors, such as 2,3-BDZs, has been an enduring quest in drug discovery. Among a few available
tools to address this speciﬁc question for making better 2,3-BDZs, perhaps the best one is to use
mechanistic clues from studies of the existing antagonists to design and discover more selective and more
potent antagonists. Here I review recent work in this area, and propose some ideas in the continuing effort
of developing newer 2,3-BDZs for tighter control of AMPA receptor activities in vivo.
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Mechanism-based design of 2,3-benzodiazepine inhibitors for AMPA receptors 5011. Ionotropic glutamate receptors and AMPA receptor
subtype
Glutamate is the major excitatory neurotransmitter in the mammalian
central nervous system (CNS). Glutamate acts through glutamate
receptors, which are divided into ionotropic glutamate receptors
(iGluRs)1 and metabotropic glutamate receptors (mGluRs)2. iGluRs
are ligand-gated ion channels, whereas mGluRs are G-protein-
coupled receptors. iGluRs can be subdivided into three classes or
subtypes after their prototypic exogenous ligands: N-methyl-D-aspar-
tic acid (NMDA), (R, S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazo-
lyl)propionic acid (AMPA) and kainic acid (KA), respectively1.
iGluRs are indispensable for brain development and activities such as
memory and learning. Dysregulation of these receptors by excessive
receptor activities, known as excitotoxicity, and/or elevated expres-
sion has been implicated in a variety of neurological disorders and
diseases, such as epilepsy, stroke, amyotrophic lateral sclerosis (ALS)
and Alzheimer's disease1. Antagonists of iGluRs are therefore drug
candidates for potential treatment of these neurological diseases. For
example, using inhibitors to block excessive AMPA receptor activity
has been shown to be neuroprotective in various disease settings3,
such as ischemia-induced cell death4, cocaine withdrawal5 and
partial-onset seizures6 (by perampanel, an FDA approved drug
branded as “Fycompa”).
Among the three subtypes of iGluRs, AMPA receptors are
known to mediate fast excitatory neurotransmission in CNS. Each
of the AMPA receptor subunits, GluA1–4 (or previously named as
GluR1–4)7, can form homomeric channels by itself or assemble
into heteromeric channels with other subunits in a tetrameric
assembly8. AMPA receptors are post-transcriptionally modiﬁed9,10
by alternative splicing11 and RNA editing12. RNA splicing and
editing are developmentally regulated, and generate additional,
functionally different receptors13–15.2. AMPA receptor antagonists
Over the past two decades, there has been a signiﬁcant progress in
developing small-molecule antagonists targeting AMPA receptors.
NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[ f ]quinoxaline-
2,3-dione), a classic competitive antagonist16, came out in late
1980s. Since then, additional competitive antagonists based on the
quinoxaline template have been made to improve potency, selectivity
and water solubility at the molecular level17,18. However, most, if not
all, of these competitive antagonists show cross activity with kainate
receptors (see reviews in Refs. 3 and 13). This may not be surprising
given that competitive antagonists bind to the same site or
“orthosteric” site to which endogenous ligand glutamate binds.
A group of antagonists that are more selective towards AMPA
receptors are 2,3-benzodiazepine derivatives, also known as GYKI
compounds3,19. The development of 2,3-BDZs has attracted more
attention, although other groups or non-2,3-BDZ types of non-
competitive antagonists were also synthesized, such as phthalazine
derivatives20. Since the ﬁrst 2,3-BDZ or GYKI 52466 appeared
more than two decades ago21, there have been hundreds of
compounds publically reported. Mostly through radio–ligand
binding experiments, these compounds are thought to be non-
competitive inhibitors. Mechanistically, noncompetitive antago-
nists are considered better suited for a more selective blockade of
AMPA receptors, because noncompetitive antagonists bind to a
regulatory site(s) distinct to the agonist site and their actions
should not depend on the concentration of an agonist. It should bepointed out that all of these small-molecule compounds are
typically drug-like and amenable to chemical optimization for oral
bioavailability and favorable pharmacokinetic properties.3. Rapid kinetic characterization of mechanism of inhibition
of AMPA receptors and their antagonists
To develop better regulatory molecules like antagonists, we have to
do kinetic studies to gain a better understanding of the mechanism of
inhibition of AMPA receptors. Measuring the kinetic rate constants of
AMPA receptor channel opening has turned out to be quite
challenging. First, a measurement must be compatible with a cellular
system where the glutamate-induced current can be followed. This is
because AMPA receptors are transmembrane proteins, and upon
binding to glutamate, small cations like Naþ and Kþ (sometime with
Ca2þ as well) permeate through the channel, thereby generating
electrical current—this is the only direct, functional signal that can be
followed. To date, an AMPA receptor channel can be conveniently
expressed in a heterologous expression system, such as human
embryonic kidney (HEK)-293 cells, to be studied with the use of
an electrophysiological recording technique22. Second, the rising
phase of the macroscopic current (from a single cell that expresses
AMPA receptors) is fast in that an AMPA channel opens in the
microsecond (ms) time region23; on the millisecond (ms) time scale,
however, the channel becomes desensitized or transiently inactivated,
while glutamate remains bound24. These intrinsic, fast channel gating
properties of AMPA receptors have made it extremely difﬁcult to
apply solution exchange or single-channel recording technique to a
study of the rate of channel opening.
To overcome relatively slow diffusion and mixing of glutamate
with AMPA receptors on a cell surface, delivered by commonly used
fast solution exchange techniques, we have developed a laser-pulse
photolysis technique with the use of a photolabile, but biologically
inert, glutamate precursor or caged glutamate (γ-O-(α-carboxy-2-
nitrobenzyl glutamate)25. Upon photolysis, the caged glutamate
liberates glutamate with a t1/2 of 30 μs26. The ensemble channel-
opening events from individual receptors on the cell surface can be
synchronized, and the glutamate-induced current can be rapidly
measured using whole-cell recording22. As a result, the channel-
opening phase can be measured within the μs time region or before
the channel-desensitization reaction that occurs in the ms time
domain. Using this technique, we are able to characterize the effect
of an inhibitor on the channel-opening (kop) and channel-closing (kcl)
rate constants of an AMPA receptor for elucidation of the mechanism
of inhibition25. For instance, an open-channel blocker will affect only
kcl but not kop, whereas a noncompetitive inhibitor will affect both kop
and kcl
25,26. The major difference between radio-ligand binding study
of a mechanism and ours is that the former is an equilibrium study
where a receptor is already desensitized if a radiolabeled agonist is
used. If a radiolabeled antagonist 27 is used in the absence of agonist,
one can only characterize the inhibitory property of an antagonist
with the closed-channel state, but not the open state, and the mode of
action of that antagonist must be a priori.4. Mechanistic insights: general properties of noncompetitive
sites on GluA2
Using rapid kinetic techniques, including the laser-pulse photolysis
technique, to time the channel activation process, we have
investigated a series of 2,3-BDZs25,26. Some important structure–
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BDZs are noncompetitive inhibitors with variable mechanistic
features associated with their sites of interaction on AMPA
receptors. By a double-inhibition experiment, we found that there
are three noncompetitive sites on an AMPA receptor (Fig. 1).
Compounds with a 4-methyl group on the 2,3-benzodiazepine ring
bind to the “M” site (red color)28; those with 4-carbonyl group bind
to the “O” site (blue color)26,29, whereas those with the 7,8-
ethylenedioxy ring (green color), instead of 7,8-methylenedioxy
ring like “O” site compounds, bind to the “E” site30. There is no
allosteric interaction among these sites. (b) Interestingly, the
inhibitors that bind to the “M” or the “E” site prefer to inhibit the
closed-channel state of a receptor, whereas those that bind to the
“O” site prefer to inhibit the open-channel state. (c) These sites have
different properties. For instance, acylation of compounds at the N-3
position of the 2,3-benzodiazepine ring for the “M” site increases
potency, but decreases the potency for those that bind to the “O” site
with the same acylating group28,29. (d) The most potent 2,3-BDZs in
our series are in the “M” site group31. Some of these compoundsFigure 1 A schematic representation of the three noncompetitive
binding sites on the an AMPA receptor for 2,3-benzodiazepine
compounds. Shown in color are three key chemical groups that
interact with partially drawn receptors, which deﬁne their sites of
binding on the receptor. The presence of both the C-4 methyl and the
7,8-methylenedioxy moiety in the 2,3-benzodiazepine structures
deﬁnes the “M” site (red color). Shown is GYKI 52466 bound to
the “M” site. The interaction between the receptor and an inhibitor at
the “M” site is stereoselective in that the “M” site preferentially
recognizes and accommodates those compounds with a C-4 methyl
group in the R conﬁguration. Replacing the C-4 methyl with a
carbonyl group results in 2,3-benzodiazepin-4-ones that bind to the
“O” site (blue color). Shown here is 1-(4-aminophenyl)-3,5-dihydro-
7,8-methylenedioxy-4 H-2,3-benzodiazepin-4-one bound to the “O”
site. Increase of the 7,8-methylenedioxy ring size into the 7,8-
ethylenedioxy one renders the resulting compound binding to the
“E” site (green color). Shown here is 1-(4-aminophenyl)-3,5-dihydro-
7,8-ethylenedioxy-4 H-2,3-benzodiazepin-4-one bound to the “E” site.have the highest potency in literature. Furthermore, the “M” is
steroselective, which prefers compounds with the R conﬁguration
for the C-4 methyl group25. Chirality can introduce higher
selectivity, and possible speciﬁcity as well for controlling the target
function in vivo (the “M” site is the only site that is chiral).5. Mechanistic insights: general properties of 2,3-BDZs
Those 2,3-BDZs that are inhibitors of AMPA receptors showed no
appreciable cross activity on either NMDA or kainate receptors.
However, there are only four compounds among those that we have
investigated thus far that also show signiﬁcant activity on GluA3 or
GluA426,28–31. However, there exists a trend that if a compound is
inhibitory on AMPA receptors, the potency is generally in the rank
order of GluA2GluA144GluA3GluA425 (see the exception
below with one special type of 2,3-BDZ). Furthermore, most of
inhibitors have a slightly higher potency on GluA2 than on GluA132.
These results suggest that the noncompetitive sites for these
compounds on GluA1 and GluA2 are similar but are different on
either GluA3 or GluA4. This conclusion is based on the assumption
that these 2,3-BDZs do not change their structures or conformations
when binding from one AMPA receptor to the other. As such, a
compound acts as a “structural probe” to measure the similarity or
difference in the same type of the noncompetitive site, like the “M”
site, among the four AMPA receptor subunits. It should be noted that
our study did not reveal the locations of these sites. Furthermore,
there is no structural data on noncompetitive sites on AMPA
receptors in literature.
Talampanel is a good example to illustrate that our results are
useful. Talampanel is perhaps the best known 2,3-BDZ33,34.
Recently, a much anticipated phase II clinical trial of this compound
for ALS (sponsored by Teva Pharmaceutical Industries) ended
without statistically signiﬁcant efﬁcacy. At the molecular level, very
few mechanistic details for talampanel were previously known3,33.
We found that talampanel inhibits GluA1 and GluA2, albeit only
weakly, but virtually does not inhibit either GluA3 or GluA425. Yet,
spinal motor neurons that undergo neurodegeneration, the patho-
genic hallmark of ALS, actually express GluA3 and GluA4, in
addition to GluA1 and GluA235. Thus, if the molecular properties of
both the AMPA receptors and talampanel are used for selecting a
single inhibitor as a drug candidate for an ALS clinical testing,
talampanel is not ideal.
We have recently reported that pairing a thiadiazole moiety with
a 2,3-benzodiazepine scaffold via the N-3 position yields an
inhibitor type with 428-fold better potency and selectivity on
AMPA receptors than either 2,3-benzodiazepine scaffold alone31 or
talampanel25. This result suggests that the “side pocket” surrounding
the “M” site on the receptor is able to accommodate a larger size of
the N-3 derivative such as a thiadiazole. One such compound we
characterized31 is shown to inhibit GluA1, 2Q, 3 and 4 AMPA
receptors with roughly a KI value of about 0.5 mmol/L. It also
inhibits equally strongly both the closed-channel and the open-
channel forms of these AMPA receptors.6. Mechanism-based design of potent 2,3-BDZs
The mechanistic clues we have learned so far can be used to
design more potent, site-speciﬁc 2,3-BDZs. Some of the superior
mechanistic features from one site may be also used to design 2,3-
BDZs that bind to other sites. Here are some predictions and ideas.
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potent 2,3-BDZs are in the “M” site group and thiadiazolyl-2,3-
BDZs are the most potent of all31. We therefore hypothesize that a
thiadiazole moiety occupies more fully the side pocket of the “M”
site, thereby generating a stronger, multivalent interaction with the
receptor site. Thiadiazole is a heterocyclic ring system, and
chemical modiﬁcations are expected to yield a large group of
thiadiazolyl derivatives from which more potent inhibitors should
be found.
Second, the same thiadiazole scaffold can be also explored for
the synthesis of “E” site compounds. In addition, the type 2
pharmacophore model36 should be reﬁned along with three distinct
noncompetitive sites on AMPA receptors (note that the “O” site and
“E” site compounds differ by a single atom enlargement of the 7,8-
methylenedioxy ring). The impact of the increase in ring size from a
dioxole to a dioxane moiety on the binding site for the resulting
compounds might reﬂect the intimate molecular contact between the
7,8-position and the receptor site. Therefore, a modulation of the
dioxole ring, i.e., the methylene group of the methylenedioxy
function, may be used to explore undiscovered, noncompetitive
binding sites as well. For example, the 7,8-methylenedioxy moiety
can be replaced with 7,8-ethylidenedioxy or 7,8-isopropylidene-
dioxy moieties. Additionally, this ring enlargement should be
explored with the “M” site compounds.
Third, kinetic evidence on both the loosely bound receptor–
inhibitor intermediate and the structure–activity relationship of the
“M” and “E” site compounds suggests that the closed-channel
state is more ﬂexible and more accommodating to 2,3-BDZs.
Targeting the closed-channel state by designing compounds that
bind to the “M” site and the “E” site is therefore a way to develop
more potent compounds. In this context, thiadiazolyl-2,3-BDZs
may be the best antagonists in that their ability of blocking AMPA
receptors is independent of agonist concentrations31.7. Developing selective antagonists of AMPA receptors
Improving selectivity (especially towards AMPA receptor sub-
units) may be the most signiﬁcant challenge of all. This challenge
can be illustrated in the following way.
Absence of high selectivity towards a disease-linked receptor or
site requires the use of a higher dosage of the drug to achieve a
sufﬁcient local concentration for efﬁcacy. Yet higher dosing promotes
the occurrence of nonspeciﬁc toxicity and other adverse side effects,
causing collateral toxicity to healthy cells/tissues37. Toxicity and a
lack of efﬁcacy are the two most common factors that drug candidates
fail38. This problem becomes especially appreciable when competi-
tive antagonists are used as drugs. Competitive antagonists must have
a sufﬁciently high afﬁnity for the target to displace an endogenous
ligand from the same binding site, and must also have a sufﬁciently
high concentration near the vicinity of the target to be effective,
especially when the concentration of ligand or agonist is high. This
means a higher dose must be administered and maintained. In
addition, if the target is a member of isoform family and the ligand
activates all isoforms, the use of a competitive antagonist generally
does not lead to selective control of the target.
High potency and high selectivity are two very desirable
properties of an inhibitor. Between the two, however, a higher
selectivity of an antagonist is perhaps more important than potency
in the context of controlling the target activity. This is especially
true for noncompetitive antagonists. For example, an apparent
potency can be augmented by the use of multiple but selectivedrug molecules, provided they bind to different sites. In this
scenario, an additive potency will be observed. If there is a
positive allosterism between or among sites, the synergistic
antagonism would be even stronger. In fact, the combinatorial
use of different, but multiple drug molecules that bind to different
noncompetitive sites of the same target, may actually provide an
additional mechanism to control a target more selectively.
On the other hand, the reward of developing highly selective
antagonists is also signiﬁcant. In this context, ﬁnding subunit-
selective antagonists for AMPA receptors should be particularly
ideal. If there are multiple antagonists with varying degrees of subunit
selectivity, a higher selectivity to target complex AMPA receptors in
varying compositions and differential expression patterns in vivo will
be possible. If multiple, separate subunits (or genes) are linked to a
disease, a unique combination of single-subunit inhibitors can be
used. These subunit-selective inhibitors provide a means for us to mix
and match for a more quantitative and tighter control of a target
function in vivo.
The use of a single, subunit-selective antagonist of AMPA
receptors as a drug candidate could be also therapeutically
beneﬁcial, because there is evidence of unique AMPA receptor
subunit involvement in various neurological conditions. For exam-
ple, global ischemia signiﬁcantly downregulates GluA2, but not
other subunits, and such a downregulation is speciﬁc in vulnerable
CA1 pyramidal neurons, which are speciﬁcally subject to ischemia-
induced neurodegeneration39. Seizure downregulates GluA2 in CA1
and CA3 pyramidal neurons before the onset of neuronal death40,41.
Signiﬁcant RNA editing defect in GluA2 has been found in spinal
motor neurons of ALS patients; in turn, Ca2þ-permeable GluA2Q
isoform is generated42. In contrast, the editing efﬁciency in normal
human control is near 100%42. A study of post-mortem samples
from multiple sclerosis patients shows that GluA3 and GluA4 are
expressed in astrocytes and MS active plaques and GluA1 is
upregulated43. All these examples illustrate that one or some, but
not all, of the AMPA receptor subunits in speciﬁc tissue regions are
often involved in a disease. Therefore, blockade of excessive
AMPA receptor activity and/or abnormal expression would be
better achieved by selectively inhibiting those subunits or channels
formed by these subunits. A generalized, promiscuous blockade of
AMPA receptors would conceivably interfere with the normal
function of AMPA receptors and cause side effects.
To date, none of the 2,3-BDZs are subunit-selective. However,
the fact that the N-3 acylated “M” site compounds (or non-
thiadiazole derivatives) prefer GluA1 and GluA2 subunits suggests
that developing subunit-preferred 2,3-BDZs should be possible.
In fact, a GluA1/2-preferred inhibitor can be useful in targeting
GluA1/2 complex channels, given that the GluA1/2 AMPA receptor
is a major receptor population found in mature hippocampus44.
Furthermore, GluA1-containing AMPA receptors are driven into
synapses by long-term potentiation (LTP) or calcium/calmodulin-
dependent protein kinase II (CaMKII) activity45. In pursuing
subunit-selective antagonists, we have explored the use of systema-
tic evolution of ligands by exponential enrichment (SELEX) to
“breed” RNA inhibitors or aptamers for AMPA receptors from a
RNA library (i.e., 1015 sequences)46. We have indeed isolated a
GluA2-selective antagonist or an RNA aptamer46. This result
demonstrated the potential of using SELEX to generate a novel
class of RNA-based, subunit-selective AMPA receptor antagonists,
alternative to small-molecule inhibitors. It should be also noted that
RNA molecules are water soluble, and are supposedly less diffusible
(chemically modiﬁed RNAs) after they are delivered locally.
However, unlike small-molecule compounds such as 2,3-BDZs,
Li Niu504RNA aptamers cannot penetrate the blood–brain barrier, and are
thus required to be delivered to CNS using other means, such as
intrathecal injection.
Additional challenges and opportunities lie ahead. Solving
structures of each of the AMPA receptor subunits to offer
noncompetitive site information will help design better inhibitors.
There are other types of AMPA receptor antagonists that are
structurally different from 2,3-BDZs. One such compound is
perampanel; it is a drug recently approved by FDA for treatment
of partial-onset seizures6. Finding additional noncompetitive sites
on AMPA receptors potentially offers additional opportunities for
design of highly selective, potent inhibitors as efﬁcacious drug
candidates with little or no side effects.
Acknowledgments
Li Niu acknowledges Dr. Sandor Solyom (CF Pharma Pharma-
ceutical, Hungary) and Professor Silvana Grasso (University of
Messina, Italy) for collaborations and for the synthesis of various
2,3-BDZs used in this study. Li Niu is supported by NIH/NINDS
Grant R01 NS060812 and a grant from Muscular Dystrophy
Association (MDA).
References
1. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM,
Ogden KK, et al. Glutamate receptor ion channels: structure, regula-
tion, and function. Pharmacol Rev 2010;62:405–96.
2. Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiol-
ogy, pharmacology, and disease. Annu Rev Pharmacol Toxicol
2010;50:295–322.
3. Solyom S, Tarnawa I. Non-competitive AMPA antagonists of 2,
3-benzodiazepine type. Curr Pharm Des 2002;8:913–39.
4. Noh KM, Yokota H, Mashiko T, Castillo PE, Zukin RS, Bennett MV.
Blockade of calcium-permeable AMPA receptors protects hippocam-
pal neurons against global ischemia-induced death. Proc Natl Acad Sci
U S A 2005;102:12230–5.
5. Conrad KL, Tseng KY, Uejima JL, Reimers JM, Heng LJ, Shaham Y,
et al. Formation of accumbens GluR2-lacking AMPA receptors
mediates incubation of cocaine craving. Nature 2008;454:118–21.
6. Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a
selective non-competitive AMPA receptor antagonist. Acta Neurol
Scand 2013;197 Suppl:19–24.
7. Collingridge GL, Olsen RW, Peters J, Spedding M. A nomenclature
for ligand-gated ion channels. Neuropharmacology 2009;56:2–5.
8. Sobolevsky AI, Rosconi MP, Gouaux E. X-ray structure, symmetry
and mechanism of an AMPA-subtype glutamate receptor. Nature
2009;462:745–56.
9. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev
Neurosci 1994;17:31–108.
10. Seeburg PH. The role of RNA editing in controlling glutamate receptor
channel properties. J Neurochem 1996;66:1–5.
11. Sommer B, Keinanen K, Verdoorn TA, Wisden W, Burnashev N,
Herb A, et al. Flip and ﬂop: a cell-speciﬁc functional switch in
glutamate-operated channels of the CNS. Science 1990;249:1580–5.
12. Sommer B, Köhler M, Sprengel R, Seeburg PH. RNA editing in brain
controls a determinant of ion ﬂow in glutamate-gated channels. Cell
1991;67:11–9.
13. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate
receptor ion channels. Pharmacol Rev 1999;51:7–61.
14. Palmer CL, Cotton L, Henley JM. The molecular pharmacology and
cell biology of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptors. Pharmacol Rev 2005;57:253–77.
15. Lambolez B, Ropert N, Perrais D, Rossier J, Hestrin S. Correlation
between kinetics and RNA splicing of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in neocortical neurons.
Proc Natl Acad Sci U SA 1996;93:1797–802.
16. Honore T, Davies SN, Drejer J, Fletcher EJ, Jacobsen P, Lodge D,
et al. Quinoxalinediones: potent competitive non-NMDA glutamate
receptor antagonists. Science 1988;241:701–3.
17. Nikam SS, Kornberg BE. AMPA receptor antagonists. Curr Med
Chem 2001;8:155–70.
18. Nikam SS, Cordon JJ, Ortwine DF, Heimbach TH, Blackburn AC,
Vartanian MG, et al. , Design and synthesis of novel quinoxaline-2, 3-
dione AMPA/GlyN receptor antagonists: amino acid derivatives. J
Med Chem 1999;42:2266–71.
19. Grasso S, De Sarro G, De Sarro A, Micale N, Zappalà M, Puia G, et al.
Synthesis and anticonvulsant activity of novel and potent 2,
3-benzodiazepine AMPA/kainate receptor antagonists. J Med Chem
1999;42:4414–21.
20. Pelletier JC, Hesson DP, Jones KA, Costa A-M. Substituted 1,
2-dihydrophthalazines: potent, selective, and noncompetitive
inhibitors of the AMPA receptor. J Med Chem 1996;39:343–6.
21. Tarnawa I, Farkas S, Berzsenyi P, Pataki Á, Andrási F. Electrophy-
siological studies with a 2, 3-benzodiazepine muscle relaxant: GYKI
52466. Eur J Pharmacol 1989;167:193–9.
22. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved
patch-clamp techniques for high-resolution current recording from
cells and cell-free membrane patches. Pﬂügers Arch 1981;391:85–100.
23. Li G, Niu L. How fast does the GluR1Qﬂip channel open? J Biol Chem
2004;279:3990–7.
24. Raman IM, Trussell LO. The mechanism of α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionate receptor desensitization after removal of
glutamate. Biophys J 1995;68:137–46.
25. Wang CZ, Niu L. Mechanism of inhibition of the GluA2 AMPA
receptor channel opening by talampanel and its enantiomer: the
stereochemistry of the 4-methyl group on the diazepine ring of 2,
3-benzodiazepine derivatives. ACS Chem Neurosci 2013;4:635–44.
26. Ritz M, Wang CZ, Micale N, Ettari R, Niu L. Mechanism of inhibition
of the GluA2 AMPA receptor channel opening: the role of 4-methyl
versus 4-carbonyl group on the diazepine ring of 2, 3-benzodiazepine
derivatives. ACS Chem Neurosci 2011;2:506–13.
27. Sheardown MJ, Nielsen EO, Hansen AJ, Jacobsen P, Honore T. 2,
3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline: a neuroprotec-
tant for cerebral ischemia. Science 1990;247:571–4.
28. Wang CZ, Sheng ZY, Niu L. Mechanism of inhibition of the GluA2
AMPA receptor channel opening: consequences of adding an N-3
methylcarbamoyl group to the diazepine ring of 2, 3-benzodiazepine
derivatives. Biochemistry 2011;50:7284–93.
29. Ritz M, Micale N, Grasso S, Niu L. Mechanism of inhibition of the
GluR2 AMPA receptor channel opening by 2, 3-benzodiazepine
derivatives. Biochemistry 2008;47:1061–9.
30. Qneibi MS, Micale N, Grasso S, Niu L. Mechanism of inhibition of
GluA2 AMPA receptor channel opening by 2, 3-benzodiazepine
derivatives: functional consequences of replacing a 7, 8-
methylenedioxy with a 7, 8-ethylenedioxy moiety. Biochemistry
2012;51:1787–95.
31. Wang CZ, Han Y, Wu A, Sólyom S, Niu L. Mechanism and site of
inhibition of AMPA receptors: pairing a thiadiazole with a 2, 3-
benzodiazepine scaffold. ACS Chem Neurosci 2014;5:138–47.
32. Wu A, Wang CZ, Niu L. Mechanism of inhibition of the GluA1
AMPA receptor channel opening by the 2, 3-benzodiazepine com-
pound GYKI 52466 and a N-methyl-carbamoyl derivative. Biochem-
istry 2014;53:3033–41.
33. Howes JF, Bell C. Talampanel. Neurotherapeutics 2007;4:126–9.
34. Bleakman D, Ballyk BA, Schoepp DD, Palmer AJ, Bath CP, Sharpe
EF, et al. Activity of 2, 3-benzodiazepines at native rat and recombi-
nant human glutamate receptors in vitro: stereospeciﬁcity and selec-
tivity proﬁles. Neuropharmacology 1996;35:1689–702.
35. Williams TL, Ince PG, Oakley AE, Shaw PJ. An immunocytochemical
study of the distribution of AMPA selective glutamate receptor
subunits in the normal human motor system. Neuroscience
1996;74:185–98.
Mechanism-based design of 2,3-benzodiazepine inhibitors for AMPA receptors 50536. Rezessy B, Solyom S. Advanced pharmacophore model of non-
competitive AMPA antagonist 2, 3-benzodiazepines. Lett Drug Des
Discov 2004;1:217–23.
37. Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A,
et al. Unexpected nanomolar inhibition of carbonic anhydrase by
COX-2-selective celecoxib: new pharmacological opportunities due to
related binding site recognition. J Med Chem 2004;47:550–7.
38. Kola I. The state of innovation in drug development. Clin Pharmacol
Ther 2008;83:227–30.
39. Gorter JA, Petrozzino JJ, Aronica EM, Rosenbaum DM, Opitz T,
Bennett MV, et al. Global ischemia induces downregulation of Glur2
mRNA and increases AMPA receptor–mediated Ca2þ inﬂux in
hippocampal CA1 neurons of gerbil. J Neurosci 1997;17:6179–88.
40. Friedman LK, Pellegrini-Giampietro DE, Sperber EF, Bennett MV,
Moshe SL, Zukin RS. Kainate-induced status epilepticus alters
glutamate and GABAA receptor gene expression in adult rat hippo-
campus: an in situ hybridization study. J Neurosci 1994;14:2697–707.
41. Grooms SY, Opitz T, Bennett MV, Zukin RS. Status epilepticus
decreases glutamate receptor 2 mRNA and protein expression inhippocampal pyramidal cells before neuronal death. Proc Natl Acad
Sci U SA 2000;97:3631–6.
42. Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, Kwak S.
Glutamate receptors: RNA editing and death of motor neurons. Nature
2004;427:801.
43. Newcombe J, Uddin A, Dove R, Patel B, Turski L, Nishizawa Y, et al.
Glutamate receptor expression in multiple sclerosis lesions. Brain
Pathol 2008;18:52–61.
44. Wenthold RJ, Petralia RS, Blahos II J, Niedzielski AS. Evidence for
multiple AMPA receptor complexes in hippocampal CA1/CA2 neu-
rons. J Neurosci 1996;16:1982–9.
45. Shi SH, Hayashi Y, Petralia RS, Zaman SH, Wenthold RJ,
Svoboda K, et al. Rapid spine delivery and redistribution of AMPA
receptors after synaptic NMDA receptor activation. Science
1999;284:1811–6.
46. Park JS, Wang CZ, Han Y, Huang Z, Niu L. Potent and selective
inhibition of a single α-amino-3-hydroxy-5-methyl-4-isoxazolepropio-
nic acid (AMPA) receptor subunit by an RNA aptamer. J Biol Chem
2011;286:15608–17.
